RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:OHHHH DEAR.... TD JUST CUT TO HOLD FROM BUYThanks for posting this... actually interesting information.
Not sure I get the connection between Red Oak and Concordia's stuff. Red Oak is for generic sourcing so it wouldn't distribute Nilandron. Red Oak would distribute their generic competition. We don't know what Cardinal Health's distribution are for Nilandron but one might suspect Cardinal might switch to the generic form. This is expected given the generic is now on the market. Not sure if that's what you were alluding to?
CNInvesting wrote: Cardinal Health is in turn in an exclusive partnership with CVS Caremark, a divison of CVS Health, in an operation called ''Red Oak Sourcing'', the largest sourcer of pharma generics in the US. As you know, they distribute CXR's Nilandron ( see Cardinal Health Specialty Pharma ).
I don't know where you get your confidence in this management buddy, but for your money's sake, hedge some.
Beckysboss wrote: Fudster, maybe CVS dropped it because it didn't sell thru their chain... immaterial to both Concordia and CVS... duhhhhh.....you can twist, turn and spin it , the retail shorts are setting up to get burned.
CVS Health confirmed this week that Nilandron®, Concordia's treatment for metastatic prostate cancer, and Dutoprol®, a treatment for high blood pressure, will be removed from CVS Health's formulary.
Concordia believes this exclusion is immaterial to its business. According to IMS prescription data, CVS did not reimburse for Nilandron® at all in the past three years and has reimbursed Dutoprol® twice in 2016.